Welcome
Pharmaceutical & Life Sciences News

Pfizer’s Neverending Hospital-Drug Woes Spell Trouble for Maker

Oct. 30, 2018, 8:08 PM

Buying Hospira was supposed to open a bright new pharmaceutical future for Pfizer Inc., but problems from the company’s past keep haunting the world’s largest drugmaker.

When Pfizer agreed to pay $17 billion to take over Hospira in 2015, the deal was presented as a bet on biosimilars—cheaper versions of brand-name biologic medications that could steal the thunder from some of Pfizer’s rivals’ biggest products. The move would position Pfizer as the biggest player in a burgeoning medical marketplace.

It hasn’t worked out that way. The biosimilar market in the U.S. has been slow to develop amid legal wrangling over...

To read the full article log in. To learn more about a subscription click here.